Company news
TG Therapeutics, Inc. news in 2022
TG Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
December 27, 2022
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 9, 2022
TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update
November 7, 2022
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
October 25, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
October 12, 2022
TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 8, 2022
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
August 24, 2022
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 7, 2022
TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update
August 4, 2022
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
June 26, 2022
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
June 2, 2022
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
May 30, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
May 25, 2022
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 19, 2022
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
April 25, 2022
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
April 14, 2022
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
April 5, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
April 3, 2022
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
March 9, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
March 3, 2022
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL
March 2, 2022
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
February 28, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 24, 2022
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
February 23, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 14, 2022
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
January 23, 2022
TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million
January 3, 2022